CHINARES PHARMA (03320.HK): tender launched for CR Pharmaceutical Commercial's potential issue, up to RMB5.5 billion

On 20 November 2026, CHINARES PHARMA (03320.HK) said the tender for CR Pharmaceutical Commercial's potential share issue launched via the China Beijing Equity Exchange, seeking up to RMB5.5 billion from no more than 15 investors, with Beijing Pharmaceutical able to join with up to RMB2 billion.

NewTimeSpace News: On 20 November 2026, China Resources Pharmaceutical Group Limited (03320.HK) provided an update on the potential issue of shares by its non-wholly-owned subsidiary, China Resources Pharmaceutical Commercial Group Co., Ltd. ("CR Pharmaceutical Commercial"). On 20 November 2026, the tender process for the potential issue was launched through the China Beijing Equity Exchange, and CR Pharmaceutical Commercial published an application for information disclosure on capital increase on the Exchange's website on the same date. The Company had published an announcement on 16 October 2026 in respect of the potential issue.

As stated in the application, it is proposed that CR Pharmaceutical Commercial issue shares in an amount of not more than RMB5.5 billion through the China Beijing Equity Exchange to not more than 15 investors (a consortium being counted as one investor). The subscription price for the potential issue shall not be lower than the asset valuation of CR Pharmaceutical Commercial as filed, and is subject to the final tender results. Beijing Pharmaceutical Group Co., Ltd., an existing shareholder of CR Pharmaceutical Commercial and a wholly-owned subsidiary of the Company, may decide, depending on the capital increase conditions, whether to participate in the potential issue concurrently by way of a non-public issue; if it does so, its subscription and investment amount shall not exceed RMB2 billion and its subscription price must be the same as that of external investors. The final size, number of investors and terms of the potential issue remain subject to the entry into subscription agreements with the subscribers.

The proposed proceeds from the potential issue will be used to fund future acquisitions, establish logistics infrastructure and repay outstanding interest-bearing debts. The board stressed that, as at the date of the announcement, CR Pharmaceutical Commercial has not entered into any binding agreement in respect of the potential issue and there is no assurance that any final transaction will proceed, and reminded shareholders and potential investors to exercise caution when dealing in the Company's securities.

×
Share to WeChat

Open WeChat, use the "Scan", and share to my Moments.